Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer. Due to the
unique cell phenotype, aggressiveness, metastatic potential and lack of receptors or targets …

Triple-negative breast cancer (TNBC), lacking specific receptors found in other breast
cancer subtypes, poses significant treatment challenges due to limited therapeutic options …

Considering the resistance and toxicity of traditional chemotherapeutic drugs, seeking
potential candidate for treating breast cancer effectively is a clinical problem that should be …

Methods In-vivo models were exposed to CA at a dose of 50 mg/kg body weight and left for 3
months till the incidence of chronic kidney disease, followed by one month of treatment with …

Background The in vivo barriers and multidrug resistance (MDR) are well recognized as
great challenges for the fulfillment of antitumor effects of current drugs, which calls for the …

We are living in an era of advanced nanoscience and nanotechnology. Numerous
nanomaterials, culminating in nanorobots, have demonstrated ingenious applications in …

According to the World Health Organization (WHO), breast cancer (BC) is the deadliest and
the most common type of cancer worldwide in women. Several factors associated with BC …

Cancer is the second biggest mortality rate globally. Most of anti-cancer drugs are
hydrophobic and when they are administered in the body, they get clear from the blood …

Hepatocellular carcinoma (HCC) remains a global health challenge and accounts for~ 90%
of liver cancers. Immunotherapy is demonstrating potent potential for HCC treatment …

Triple-negative breast cancer (TNBC), a unique type of breast cancer, is defined by the
absence of ER, PR, and HER2 receptors in the tumor. This particularly aggressive form of …